PubMed-listed publications can be found here.
The rest of the published work, incl. technical proceedings, can be found through Google Scholar.

Most recent from us:
Kukkonen et al. 2022 Endocrine Related Cancer: Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen.
Scaravilli et al. 2022 Oncogenesis: miR-32 promotes MYC-driven prostate cancer.
Ruusuvuori et al. 2022 Heliyon: Spatial analysis of histology in 3D: quantification and visualization of organ and tumor level tissue environment.
Batnasan et al. 2022 Results Probl Cell Differ: Nuclear Organization in Response to Stress: A Special Focus on Nucleoli.
Schirmer et al. 2022 Front. Cell Devl Biol: Nuclear size rectification: A potential new therapeutic approach to reduce metastasis in cancer.
Tollis et al. 2022 ACS Chemical Biology: Chemical Interrogation of Nuclear Size Identifies Compounds with Cancer Cell Line-Specific Effects on Migration and Invasion.
Latonen and Ruusuvuori, 2021 European Journal of Cancer: Building a central repository landmarks a new era for AI-assisted digital pathology development in Europe.
Liimatainen et al. 2021 BMC Cancer: Virtual reality for 3D histology: multi-scale visualization of organs with interactive feature exploration.
Sadeesh et al. 2021 Cancers: Proteomic Landscape of Prostate Cancer: The View Provided by Quantitative Proteomics, Integrative Analyses, and Protein Interactomes.
Rintala et al. 2021 Brief Bioinform: A systematic comparison of data- and knowledge-driven approaches to disease subtype discovery.
Eerola et al. 2021 Cancer Med: Expression and ERG regulation of PIM kinases in prostate cancer.
Scaravilli et al. 2021 Front. Cell Dev. Biol: Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer.
Liimatainen et al. 2021 Biomolecules: Convolutional Neural Network-Based Artificial Intelligence for Classification of Protein Localization Patterns.
Uusi-Mäkelä et al. 2020 bioRxiv 2020.09.08.287268: Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progression.